BRIEF published on 06/14/2024 at 22:50, 2 years 4 months ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase® Shareholders Theralase® Virtual Meeting AGSM Zoom Presentation
PRESS RELEASE published on 06/14/2024 at 22:45, 2 years 4 months ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R) Theralase Technologies Inc. provides a reminder for its Annual General and Special Meeting to be held on June 19th, 2024, with a virtual Zoom presentation including a Q&A session for shareholders Annual General Meeting Shareholders Theralase Technologies Inc. AGSM Virtual Zoom Presentation
BRIEF published on 06/12/2024 at 13:05, 2 years 4 months ago Rutherrin® Increases Efficacy of Chemotherapy Cancer Treatment Chemotherapy Rutherrin® Multidrug Resistance Theralase® Technologies
PRESS RELEASE published on 06/12/2024 at 13:00, 2 years 4 months ago Rutherrin(R) Increases Efficacy of Chemotherapy Theralase Technologies announces preclinical success of Rutherrin® in enhancing chemotherapy efficacy and reducing multidrug resistance in cancer cells Cancer Treatment Theralase Technologies Rutherrin® Multidrug Resistance Chemotherapy Efficacy
BRIEF published on 06/10/2024 at 13:05, 2 years 4 months ago Ruvidar(TM) Enhances Efficacy of Cancer Drug Cancer Treatment Theralase Technologies Ruvidar(TM) BCG NMIBC
PRESS RELEASE published on 06/10/2024 at 13:00, 2 years 4 months ago Ruvidar(TM) Enhances Efficacy of Cancer Drug Theralase® Technologies Inc. announces breakthrough in cancer research by developing RuBCG compound to enhance efficacy of bladder cancer treatment. Preclinical results show promising potential Theralase Technologies Inc. Cancer Research RuBCG Compound Bladder Cancer Treatment Preclinical Results
BRIEF published on 06/06/2024 at 13:05, 2 years 4 months ago Theralase Successfully Destroys Lung Cancer Preclinical Study Theralase Technologies Lung Cancer Rutherrin®
PRESS RELEASE published on 06/06/2024 at 13:00, 2 years 4 months ago Theralase(R) Successfully Destroys Lung Cancer Theralase® Technologies Inc. announces preclinical success with Rutherrin® compound in targeting Non-Small Cell Lung Cancer. Results show improved tumour destruction and slower progression Theralase Technologies Inc. Cancer Treatment Preclinical Study NSCLC Rutherrin Compound
BRIEF published on 06/04/2024 at 13:05, 2 years 4 months ago Theralase® Technology Effective in Virus Inactivation Theralase Ruvidar Antiviral Research Virus Inactivation Heliyon
PRESS RELEASE published on 06/04/2024 at 13:00, 2 years 4 months ago Theralase(R) Technology Effective in Virus Inactivation Theralase Technologies Inc. announces successful inactivation of various viruses with lead compound RuvidarTM through peer-reviewed research. Potential for viral vaccine development highlighted Theralase Technologies Inc. RuvidarTM Peer-Reviewed Research Viral Inactivation Viral Vaccine Development
Published on 10/30/2026 at 23:35, 2 days 1 hour ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 1 hour ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 5 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 9 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 14 hours 20 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 19 hours 55 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 8 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 2 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days 1 hour ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 2 days 12 hours ago Capital increase through exercise of subscription rights
